Free Trial

Atossa Therapeutics (ATOS) Stock Price, News & Analysis

-0.03 (-1.53%)
(As of 10:40 AM ET)
Today's Range
50-Day Range
52-Week Range
223,190 shs
Average Volume
1.37 million shs
Market Capitalization
$201.84 million
P/E Ratio
Dividend Yield
Price Target

Atossa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
235.4% Upside
$5.50 Price Target
Short Interest
9.10% of Shares Sold Short
Dividend Strength
News Sentiment
0.77mentions of Atossa Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$44,250 Bought Last Quarter
Proj. Earnings Growth
From ($0.23) to ($0.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

600th out of 921 stocks

Pharmaceutical Preparations Industry

272nd out of 415 stocks

ATOS stock logo

About Atossa Therapeutics Stock (NASDAQ:ATOS)

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

ATOS Stock Price History

ATOS Stock News Headlines

Atossa Therapeutics (NASDAQ:ATOS) Upgraded at
5 Micro-Cap Healthcare Stocks Insiders Are Buying
See More Headlines
Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.73 per share


Free Float
Market Cap
$204.99 million

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Steven C. Quay FCAP (Age 73)
    M.D., Ph.D., Chairman, CEO & President
    Comp: $1.14M
  • Ms. Heather Rees (Age 52)
    SVP, Finance & Principal Accounting Officer
  • Ms. Delly Behen P.H.R.
    Senior Vice President of Administration & HR
  • Mr. Eric Van Zanten
    Vice President of Investor & Public Relations
  • Dr. Richard Graydon M.D.
    Ph.D., Interim Chief Medical Officer

ATOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Atossa Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATOS shares.
View ATOS analyst ratings
or view top-rated stocks.

What is Atossa Therapeutics' stock price target for 2024?

2 brokers have issued 1-year price objectives for Atossa Therapeutics' shares. Their ATOS share price targets range from $5.00 to $6.00. On average, they predict the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 235.4% from the stock's current price.
View analysts price targets for ATOS
or view top-rated stocks among Wall Street analysts.

How have ATOS shares performed in 2024?

Atossa Therapeutics' stock was trading at $0.88 at the beginning of the year. Since then, ATOS stock has increased by 86.4% and is now trading at $1.64.
View the best growth stocks for 2024 here

When is Atossa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ATOS earnings forecast

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02.

When did Atossa Therapeutics' stock split?

Shares of Atossa Therapeutics reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).

Who are Atossa Therapeutics' major shareholders?

Atossa Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.59%), Virtu Financial LLC (0.07%), PFG Investments LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gregory L Weaver and Jonathan Finn.
View institutional ownership trends

How do I buy shares of Atossa Therapeutics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATOS) was last updated on 5/22/2024 by Staff

From Our Partners